Stephen T. Worland - 13 May 2022 Form 4 Insider Report for eFFECTOR Therapeutics, Inc.

Role
President and Chief Executive, Director
Signature
/s/ Michael Byrnes, Attorney-in-Fact for Stephen T. Worland
Issuer symbol
EFTR on OTC
Transactions as of
13 May 2022
Net transactions value
+$2,811
Form type
4
Filing time
17 May 2022, 20:44:14 UTC
Previous filing
24 Jan 2022
Next filing
09 Jun 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EFTR Common Stock Award $2,811 +1,837 +0.95% $1.53 194,978 13 May 2022 Direct F1, F2
holding EFTR Common Stock 562,339 13 May 2022 By Trust F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were acquired under the eFFECTOR Therapeutics, Inc. 2021 Employee Stock Purchase Plan.
F2 The Form 4 previously filed on behalf of the Reporting Person on August 27, 2021 inadvertently overstated the number of shares held directly following the transactions reported therein. This reflects the correct number of shares directly and indirectly held by the Reporting person following the previously reported transactions and the transaction reported herein.